For Updates follow us on:
NEWER DRUGS 2015:
Edoxaban – Oral factor Xa inhibitor approved for DVT, pulmonary embolism and stroke prophylaxis in atrial fibrillation.
• Secukinumab – Anti IL 17 Ab approved for Psoriasis
• Isavuconazonium – Azole approved for invasive Aspergillosis and mucormycosis
• Avibactam – With Ceftazidime
• Panobinostat – Histone deacetylase inhibitor for multiple myeloma.
• Cobicistat – Its a CYP3A4 inhibitor approved for use with Atazanavir and Darunavir to increase their half life.
• Palbociclib – Cyclin dependent kinase inhibitor approved for ER/PR positive breast in post menopausal female in combination with aromatase inhibitor.
• Lenvatinib – VEGFR TK inhibitor approved for recurrent or metastatic thyroid ca refractory to I131.
• Nivolumab – Anti PD1 receptor Ab approved for metastatic squammous non small cell ca lung.
• Dinutuximab – Anti GD2 glycolipid Ab approved for neuroblastoma.
• Ivabridine – Inhibitor of If current in SA node… Approved for CHF and angina.
• Sacubitril – Inhibitor of neutral endopeptidase (neprilysin), combined with ARB for treatment of CHF.
• Alirocumab – Anti PCSK 9 Ab used to decrease LDL in familial hypercholesterolemia and CVS atherosclerotic disorders. PCSK 9 is a protein responsible for LDL receptors degradation in liver.
• Sonidegib – Hedgehog pathway inhibitor used for treatment of basal cell carcinoma recurrence after surgery and radiotherapy.
• Flibanserin – 5HT 1A agonist and 5HT 2C antagonist for hypoactive sexual desire disorder (HSDD).
• Paritaprevir – It is a Hep C virus protease inhibitor.
•Daclatasvir, Ombitasvir – NS5A protein inhibitors of hep C virus.
1. Daclatasvir is approved to be used with sofosbuvir for Hep C infection.
2. Ombitasvir is approved to be used with paritaprevir and ritonavir for Hep C virus infection.
• Brexpiprazole – Atypical antipsychtic approved for treatment of schizophrenia and depression.